Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
219 Leser
Artikel bewerten:
(0)

Single-use Bioreactors Market 2017 - Global Forecast to 2022: Key Players are Sartorius Stedim Biotech, Merck Millipore, GE Healthcare, Danaher and Thermo Fisher Scientific

DUBLIN, Dec. 5, 2017 /PRNewswire/ --

The "Single-use Bioreactors Market by Product, Type of Molecule, Type of Cell, Type, Application, End User - Global Forecast to 2022" report has been added to Research and Markets' offering.

Research and Markets Logo

The global single-use bioreactors market is projected to reach 2,685.1 Million by 2022 from USD 997.6 Million in 2017, at a CAGR of 21.9%.

Single-use bioprocessing, which emerged in the 1970s with the use of vials and pipettes, has transformed significantly over the last decade. Single-use bioprocessing is a rapidly evolving technology used in the development of disposable bioprocessing equipment and accessories to manufacture biopharmaceutical products. These disposable equipment mainly help to reduce costs associated with the sterilization, cleaning, and maintenance of steel-based bioreactor systems and accessories. Increasing adoption of SUBs among small companies and startups and reduced automation complexity are the major factors driving the adoption of single-use bioreactors.

In this report, the global single-use bioreactors market is segmented on the basis of product, type, type of cell, type of molecule, application, end user, and region. Based on product, the single-use bioreactors market is segmented into single-use bioreactor systems, media bags, and filtration assemblies.

In 2017, the single-use bioreactor systems segment is expected to account for the largest share of the market. The numerous advantages such as the elimination of validation issues, shortened downtime and turnaround time, and lowered risk of cross-contamination due to the use of new bags for each run has resulted in the increase in the adoption of single-use systems by biopharmaceutical companies.

The key players in the single-use bioreactors market include Sartorius Stedim Biotech (France), Merck Millipore (Germany), GE Healthcare (US), Danaher (US), and Thermo Fisher Scientific (US).

Market Dynamics

Drivers

  • Increasing Adoption of Subs Among Small Companies and Startups
  • Reduced Automation Complexity
  • Ease in Cultivation of Marine Organisms
  • Reduced Environmental Impact

Restraints

  • Regulatory Concerns Related to Subs
  • Issues Regarding Leachables and Extractables

Opportunities

  • Growing Biologics Market
  • Patent Expiry

Challenges

  • Need for Improved Single Use Sensors
  • Standardization of Single Use Designs

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Single Use Bioreactor Market, By Product

7 Single Use Bioreactor Market, By Type

8 Single Use Bioreactor Market, By Type of Cell

9 Single Use Bioreactor Market, By Type of Molecule

10 Global Single Use Bioreactor Market, By Application

11 Global Single Use Bioreactor Market, By End User

12 Global Single Use Bioreactor Market, By Region

13 Competitive Landscape

14 Company Profiles

  • Applikon Biotechnology
  • Cellexus
  • Celltainer Biotech
  • Cesco Bioengineering
  • Danaher
  • Distek
  • Eppendorf
  • GE Healthcare
  • Merck Millipore
  • Parker Hannifin
  • PBS Biotech
  • Pierre Guerin
  • Sartorius Stedim Biotech
  • Solida Biotech
  • Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/research/tlm97g/singleuse

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.